Study suggests some over-the-counter throat lozenges may help reduce transmission of COVID-19

The preliminary findings indicated the highest concentration BH/CPC lozenge solution tested reduced SARS-CoV-2 viral load by 99.99% in one minute. This was based on testing conducted in a defined and controlled laboratory environment, designed to mimic the conditions of the oral cavity.

The tested solutions showed important virucidal (virus killing) activity against SARS-CoV-2 in the laboratory study, suggesting the possibility of them reducing the amount of virus in the oral cavity as well as reducing the risk of viral transmission.

With these promising findings, researchers suggest further investigation into the BH/CPC lozenge’s viricidal activity is warranted.

It is important to note the study is yet to be peer-reviewed, however the results are extremely encouraging and a positive step in finding ongoing ways to manage the spread of COVID-19, which may include simple and readily available options such as medicated sore throat lozenges.

iNova Pharmaceuticals’ Regional Medical Affairs Specialist, Sue Low, welcomed these findings. “While more clinical trials need to be conducted, we follow with interest the research being conducted on ingredients like CPC and BH throughout the world.

Handwashing, social distancing and mask-wearing are the current mainstays for the reduction of viral spread, and we look forward to seeing what the latest science can offer us in terms of additional tools. We encourage consumers to discuss the availability of lozenges that suit their needs with their health professional, and to always read the label and follow the directions for use.”